CTOs on the Move


 
Zygote is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.zygote.com
  • 350 S 400 W Ste 101
    Lindon, UT USA 84042
  • Phone: 801.765.4141

Executives

Name Title Contact Details

Similar Companies

JMA

JMA is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oxford Finance Corporation

Oxford Finance Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Tao Life Sciences

TAO Life Sciences invests in and develops early stage medical innovations. Working closely with physicians and researchers from universities and companies, TAO Life Sciences takes new concepts and turns them into reality. TAO Life Sciences is building a pipeline of promising medical device and life science innovations that will impact global healthcare markets and make a significant difference in people's lives. TAO Life Sciences applies its expertise to develop prototypes, demonstrate clinical proof of concept, and secure financial exits for our innovations. We bring design engineering, scientific direction, and business and legal strategy to clinicians' and researchers' new design concepts. In doing so, we have built a diversified pipeline of medical device technologies with significant commercial potential. The Company's principals have successfully brought medical device, diagnostic, therapeutic and other products to market over the past twenty years.

Immunovant

Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.

Onconano Medicine

OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease.